Log in to search using one of your social media accounts:

 

Triglide (Fenofibrate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 7, 2017 Category: Drugs & Pharmacology Source Type: news

Fenoglide (Fenofibrate Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 7, 2017 Category: Drugs & Pharmacology Source Type: news

Antara (Fenofibrate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 7, 2017 Category: Drugs & Pharmacology Source Type: news

Fenofibrate may reduce heart disease risk in some patients with type 2 diabetes
A new study shows that the drug fenofibrate might reduce the risk of cardiovascular events in patients with type 2 diabetes who have high levels of triglycerides and low levels of'good'cholesterol, despite being treated with statins. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 28, 2016 Category: Science Source Type: news

Fenofibrate may reduce heart disease risk in some patients with type 2 diabetes
(NIH/National Heart, Lung and Blood Institute) A new study shows that the drug fenofibrate might reduce the risk of cardiovascular events in patients with type 2 diabetes who have high levels of triglycerides and low levels of 'good' cholesterol, despite being treated with statins. The study, funded by the National Heart, Lung, and Blood Institute (NHLBI), appears in the Dec. 28 issue of JAMA Cardiology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 28, 2016 Category: Global & Universal Source Type: news

fenofibrate (Antara, Fenoglide, Fibricor, Lipofen, Lofibra, Tricor, Triglide, Trilipix)
Title: fenofibrate (Antara, Fenoglide, Fibricor, Lipofen, Lofibra, Tricor, Triglide, Trilipix)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 10/31/2016 12:00:00 AM (Source: MedicineNet Cholesterol General)
Source: MedicineNet Cholesterol General - October 31, 2016 Category: Cardiology Source Type: news

Fenofibrate 40 mg/ 120 mg (Fenofibrate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 6, 2016 Category: Drugs & Pharmacology Source Type: news

Tricor (Fenofibrate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 22, 2016 Category: Drugs & Pharmacology Source Type: news

Mylan Launches Generic Fenoglide(R) Tablets
HERTFORDSHIRE, England and PITTSBURGH, July 6, 2016 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Fenofibrate Tablets USP, 40 mg and 120 mg, which is a generic version of Santarus's Fenoglid... Biopharmaceuticals, Generics, FDA, Product LaunchMylan, Fenofibrate, Fenoglide, hypercholesterolemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 6, 2016 Category: Pharmaceuticals Source Type: news

Researchers develop novel, non-toxic approach to treating variety of cancers
A novel, non-toxic approach to treating a wide variety of cancers has been identified by a team of researchers. The treatment approach is based on a combination therapy of the sugar 2-Deoxy-D-glucose (2-DG) and fenofibrate, a well-studied cholesterol medication. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 18, 2016 Category: Science Source Type: news

Sylvester researchers develop novel, non-toxic approach to treating variety of cancers
(University of Miami Miller School of Medicine) A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers. The treatment approach is based on a combination therapy of the sugar 2-Deoxy-D-glucose (2-DG) and fenofibrate, a well-studied cholesterol medication. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 18, 2016 Category: Global & Universal Source Type: news

Aurobindo Pharma gets final USFDA nod for cholesterol drug
"The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Fenofibrate Tablets, 48 mg and 145 mg," Aurobindo Pharma said (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 6, 2016 Category: Pharmaceuticals Source Type: news

A promising new treatment for high triglycerides
When you think about fat circulating in the bloodstream, you might immediately think of cholesterol. But there’s another type of fat you shouldn’t ignore: triglycerides. As with cholesterol, high triglycerides can also increase the risk of having a heart attack. Existing drugs for lowering triglycerides aren’t that good at reducing heart attack risk. That’s why a report on a new way to lower triglycerides, published in today’s New England Journal of Medicine, is generating some excitement among cardiologists. What are triglycerides? Triglycerides are a type of fat that circulates in the bloods...
Source: New Harvard Health Information - July 29, 2015 Category: Consumer Health News Authors: Gregory Curfman, MD Tags: Heart Health high triglycerides Source Type: news

Repurposed anti-cholesterol drug could improve treatment-resistant anemias
Diamond Blackfan anemia (DBA), a rare inherited bone marrow failure syndrome, is usually diagnosed during childhood and is typically treated with glucocorticoids that cause a host of unwanted, often dangerous side effects. Using a mouse model, a research team has now determined that combining the cholesterol-lowering drug fenofibrate with glucocorticoids could allow for dramatically lower steroid doses in the treatment of DBA and other erythropoietin-resistant anemias. These promising results are the foundation for a clinical trial that will begin soon. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 11, 2015 Category: Science Source Type: news

International Fenofibrate Market Status & Forecast Report...
2015 Global Fenofibrate Industry Research Report of 168 pages now readily available at DeepResearchReports.com database.(PRWeb April 07, 2015)Read the full story at http://www.prweb.com/releases/global-fenofibrate-market/2015-research-report/prweb12635946.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 7, 2015 Category: Pharmaceuticals Source Type: news

Common cholesterol drug stimulates the same receptors as marijuana
(Federation of American Societies for Experimental Biology) If you want the benefits of medical marijuana without the 'unwanted side effects' of cannabis, new research should leave you on a high note. According to a research report appearing in the April 2015 issue of The FASEB Journal, fenofibrate, also known by the brand name Tricor, may benefit a wide range of health issues, such as pain, appetite stimulation, nausea, as well as immune and various psychiatric and neurological conditions. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 1, 2015 Category: Biology Source Type: news

fenofibrate (Antara, Fenoglide, Fibricor, Lipofen, Lofibra, Tricor, Triglide, Trilipix)
Title: fenofibrate (Antara, Fenoglide, Fibricor, Lipofen, Lofibra, Tricor, Triglide, Trilipix)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 11/11/2014 12:00:00 AM (Source: MedicineNet Cholesterol General)
Source: MedicineNet Cholesterol General - November 11, 2014 Category: Cardiology Source Type: news

Ranbaxy Laboratories gets USFDA nod to sell cholesterol medicine
Ranbaxy received approval from USFDA to manufacture & market Fenofibrate capsules used for lowering high cholesterol & triglyceride levels in blood. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 5, 2014 Category: Pharmaceuticals Source Type: news

Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now...
LifeScienceIndustryResearch.com adds Latest Report on “Market Research Report on Global and Chinese Fenofibrate (CAS 49562-28-9) Industry, 2009-2019” to its store. Inquire Before Buying at...(PRWeb September 21, 2014)Read the full story at http://www.prweb.com/releases/fenofibrate-market/2009-2019/prweb12184231.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 21, 2014 Category: Pharmaceuticals Source Type: news

Fibrate Seems to Reduce CVD Risk in Diabetic Women
(MedPage Today) -- Contrary to earlier results, fenofibrate may actually lower cardiovascular risk in women with type 2 diabetes, researchers found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 19, 2014 Category: Cardiology Source Type: news

Fenofibrate also effective for women with type 2 diabetes
Blood-fat lowering drug fenofibrate is beneficial for women with type 2 diabetes, according to new research. (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - August 19, 2014 Category: Nursing Source Type: news

Fenofibrate Works as Well in Women With Diabetes as in MenFenofibrate Works as Well in Women With Diabetes as in Men
Fenofibrate appears to work as well in women with type 2 diabetes as in men, according to a new FIELD analysis, providing reassurance after the ACCORD Lipid trial. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 18, 2014 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Fenofibrate and Renal DiseaseFenofibrate and Renal Disease
Find out more about the potentially cardioprotective effects of fenofibrate for patients with type 2 diabetes. Clinical Lipidology (Source: Medscape Nephrology Headlines)
Source: Medscape Nephrology Headlines - January 11, 2014 Category: Urology & Nephrology Tags: Cardiology Journal Article Source Type: news

HDL-C Lowering Seen in Some Patients on Fibrate/TZD ComboHDL-C Lowering Seen in Some Patients on Fibrate/TZD Combo
Data from the ACCORD trial suggest that in a small number of patients, perhaps with a particular genetic background, the combination of fenofibrate and a TZD dramatically lowers HDL cholesterol. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 9, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Odd HDL Finding Seen in Diabetes Trial (CME/CE)
(MedPage Today) -- Among patients with type 2 diabetes, treatment with both fenofibrate and a thiazolidinedione was paradoxically tied to a higher likelihood of having an extremely low HDL cholesterol level, researchers found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 4, 2013 Category: Cardiology Source Type: news

World First Approval for Fenofibrate in Diabetic RetinopathyWorld First Approval for Fenofibrate in Diabetic Retinopathy
The established cholesterol-lowering drug fenofibrate has received first approval globally to slow the progression of diabetic retinopathy in patients with type 2 diabetes in Australia. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 29, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Fish Oil vs. Drugs for Hypertriglyceridemia in HIV+ PatientsFish Oil vs. Drugs for Hypertriglyceridemia in HIV+ Patients
Is fish oil as effective as fenofibrate, gemfibrozil, and atorvastatin in reducing triglyceride levels in HIV patients? JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 8, 2013 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news

Antara (Fenofibrate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 4, 2013 Category: Drugs & Pharmacology Source Type: news

EMA Panel Gives Thumbs-up to Fenofibrate/Simvastatin ComboEMA Panel Gives Thumbs-up to Fenofibrate/Simvastatin Combo
The drug, known as Cholib, received a "positive opinion" from CHMP for two doses of the fenofibrate/simvastatin combination. A positive opinion is a prerequisite to approval by the European Commission, which has 67 days from the date of the opinion to grant approval. International Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 28, 2013 Category: Cardiology Tags: Cardiology News Alert Source Type: news

EMA advisory committee gives thumbs-up to fenofibrate/simvastatin combo
The drug, known as Cholib, received a "positive opinion" from CHMP for two doses of the fenofibrate/simvastatin combination. A positive opinion is a prerequisite to approval by the European Commission, which has 67 days from the date of the opinion to grant approval. (Source: theHeart.org)
Source: theHeart.org - June 28, 2013 Category: Cardiology Source Type: news

Mylan Launches Generic Antara® Capsules
Mylan Inc. (Nasdaq:MYL) today announced that its subsidiary Mylan Pharmaceuticals has begun shipping Fenofibrate Capsules USP, 43 mg and 130 mg. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 26, 2013 Category: Pharmaceuticals Source Type: news